Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Diabetes
•
Endocrinology
Do you recommend up-titrating the Metformin dose of patients with T2DM who are at goal A1c in order to decrease their risk of diabetes-related delirium?
https://doi.org/10.2337/dc24-1414
Related Questions
Is Metformin contraindicated in patients using long term oxygen therapy at home?
Does oral semaglutide provide similar cardiovascular risk reduction benefits as injectable semaglutide?
Is there a role for use of GLP1 R agonist or dual agonist therapy for management of post bariatric hypoglycemia and dumping syndrome?
Is GLP-1 therapy a viable treatment option for a patient with Type 2 Diabetes complicated by atherosclerotic heart disease and cholelithiasis?
What is the clinical importance of differentiating between impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) states?
When and how should we be stopping GLP-1 Receptor Agonist/Dual Agonist therapy?
Outside of teplizumab, what therapies do you recommend for preserving beta cell function in patients with early stage type 1 diabetes mellitus?
When do you recommend screening patients with T2DM for heart failure?
How many days prior to surgery do you recommend stopping SGLT2 inhibitors and when is it safe to resume therapy?
Can rapid weight loss following GLP1 R agonist therapy lead to postprandial hypoglycemia and if so, what are the treatment options outside of dietary modifications?
